Scottish life science company Biocaptiva has secured £2.1m from an oversubscribed additional funding round.
The University of Edinburgh spin-out is developing BioCaptis, a cell-free DNA capture device aimed at transforming liquid biopsy testing for cancer management.
The financing was led by existing investor Archangels, joined by Scottish Enterprise and Cancer Research Horizon, the new innovation engine of Cancer Research UK, alongside new investor Old College Capital, the University of Edinburgh’s in-house venture fund.